Table 1. Demographic and clinical characteristics of the patients (n = 94).
| Parameter | Mean ± SD (range) |
|---|---|
| Female gender n (%) | 92 (97.9) |
| Age (years) | 59.26 ±1.05 (35–85) |
| Length of Disease (months) | 60.45 ± 48.31 (12–246) |
| ALT IU/L | 30.94 ±23.43 (6–145) |
| AST IU/L | 34.77 ± 90.53 (8–215) |
| ALP IU/L | 154.65 ± 92.36 (63–508) |
| GGT IU/L | 62.90 ± 89.57 (12–692) |
| Total Bilirubin μmol/L | 19.10 ± 33.68 (2.7–251.1) |
| Albumin g/L | 39.95 ± 6.26 (15.7–68) |
| INR | 1.02 ± 0.22 (0.08–2) |
| PT (seconds) | 12.88 ± 3.24 (10.2–31.4) |
| Mayo Risk Score | 4.34 ± 2.26 |
| Histopathological stage: | n (%) |
| 1 | 34 (48.6) |
| 2 | 14 (20) |
| 3 | 8 (11.4) |
| 4 | 14 (20) |
| AMA: | |
| Positive | 76 (86.4) |
| Negative | 12 (13.6) |
| ANA Hep2: | |
| Positive | 45 (54.9) |
| Negative | 37 (45.1) |
ALT: alanine aminotransferase, AST: aspartate aminotransferase, ALP: alkaline phosphatase, GGT: γ-glutamyltransferase, INR: international normalized ratio, PT: prothrombin time, AMA: anti-mitochondrial antibodies, ANA Hep2: anti-nuclear antibody Hep2